Shares of Recro Pharma Inc (NASDAQ:REPH) have earned a consensus recommendation of “Buy” from the seven ratings firms that are covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $12.70.
REPH has been the subject of several research reports. ValuEngine upgraded shares of Recro Pharma from a “hold” rating to a “buy” rating in a research note on Friday, May 24th. Oppenheimer set a $20.00 price objective on shares of Recro Pharma and gave the stock a “buy” rating in a research note on Friday, August 9th. Zacks Investment Research upgraded shares of Recro Pharma from a “hold” rating to a “buy” rating and set a $13.00 target price for the company in a research note on Thursday, August 15th. Finally, BidaskClub downgraded shares of Recro Pharma from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 31st.
Several hedge funds have recently made changes to their positions in REPH. Nuveen Asset Management LLC purchased a new position in shares of Recro Pharma in the second quarter valued at $3,455,000. River & Mercantile Asset Management LLP purchased a new position in shares of Recro Pharma in the second quarter valued at $2,166,000. BlackRock Inc. boosted its stake in shares of Recro Pharma by 14.9% in the second quarter. BlackRock Inc. now owns 1,292,173 shares of the specialty pharmaceutical company’s stock valued at $13,142,000 after purchasing an additional 167,346 shares during the period. Wedge Capital Management L L P NC purchased a new position in shares of Recro Pharma in the second quarter valued at $1,682,000. Finally, Penn Capital Management Co. Inc. bought a new position in Recro Pharma during the 2nd quarter valued at $1,525,000. Institutional investors and hedge funds own 60.50% of the company’s stock.
Shares of Recro Pharma stock traded up $0.10 during mid-day trading on Thursday, hitting $12.09. 3,857 shares of the stock were exchanged, compared to its average volume of 288,290. Recro Pharma has a twelve month low of $5.53 and a twelve month high of $12.67. The stock has a market capitalization of $270.48 million, a price-to-earnings ratio of -4.84 and a beta of -0.30. The company has a 50-day simple moving average of $10.99 and a 200 day simple moving average of $9.53.
Recro Pharma (NASDAQ:REPH) last released its quarterly earnings results on Thursday, August 8th. The specialty pharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.42) by $0.29. Recro Pharma had a negative net margin of 64.26% and a negative return on equity of 472.45%. The company had revenue of $31.26 million for the quarter, compared to analysts’ expectations of $24.06 million. As a group, equities research analysts expect that Recro Pharma will post -0.35 earnings per share for the current year.
Recro Pharma Company Profile
Recro Pharma, Inc, a specialty pharmaceutical company, develops and commercializes products for hospital and related acute care settings. The company operates in two segments, Acute Care, and Contract Development and Manufacturing. Its lead product candidate includes injectable meloxicam, which completed pivotal phase III clinical trials for the treatment of post-operative pain.
Receive News & Ratings for Recro Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma and related companies with MarketBeat.com's FREE daily email newsletter.